Prothena Plc logo

Prothena Plc Share Price Today

(NASDAQ: PRTA)

Prothena Plc share price is $14.95 & ₹1,300.19 as on 6 Mar 2025, 2.30 'hrs' IST

$14.95

-0.11

(-0.73%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Prothena Plc share price in Dollar and Rupees. Guide to invest in Prothena Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Prothena Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Prothena Plc share price movements

  • Today's Low: $14.33
    Today's High: $15.46

    Day's Volatility :7.31%

  • 52 Weeks Low: $11.70
    52 Weeks High: $30.85

    52 Weeks Volatility :62.08%

Prothena Plc (PRTA) Returns

PeriodProthena Corporation PlcSector (Health Care)Index (Russel 2000)
3 Months
7.32%
3.7%
0.0%
6 Months
-27.92%
-2.8%
0.0%
1 Year
-49.05%
2.5%
0.0%
3 Years
-50.61%
12.9%
-11.6%

Prothena Plc (PRTA) Key Statistics

in dollars & INR

Previous Close
$15.06
Open
$15.03
Today's High
$15.46
Today's Low
$14.33
Market Capitalization
$804.7M
Today's Volume
$572.0K
52 Week High
$30.8548
52 Week Low
$11.7
Revenue TTM
$135.2M
EBITDA
$-153.7M
Earnings Per Share (EPS)
$-2.27
Profit Margin
-90.5%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-23.34%

How to invest in Prothena Plc Stock (PRTA) from India?

It is very easy for Indian residents to invest directly in Prothena Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Prothena Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Prothena Plc or PRTA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Prothena Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Prothena Plc shares which would translate to 0.058 fractional shares of Prothena Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Prothena Plc, in just a few clicks!

Returns in Prothena Plc (PRTA) for Indian investors in Rupees

The Prothena Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Prothena Plc investment value today

Current value as on today

₹55,903

Returns

₹44,097

(-44.1%)

Returns from Prothena Plc Stock

₹49,046 (-49.05%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Prothena Plc (PRTA)

-72%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Prothena Plc Stock from India on INDmoney has decreased by -72% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Prothena Plc

  • EcoR1 Capital, LLC

    21.52%

  • FMR Inc

    14.99%

  • Wellington Management Company LLP

    9.53%

  • BlackRock Inc

    7.66%

  • T. Rowe Price Associates, Inc.

    6.85%

  • Armistice Capital, LLC

    4.15%

Analyst Recommendation on Prothena Plc

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Prothena Plc(by analysts ranked 0 to 5 stars)

Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
14
14
Hold
4
4
4
Sell
0
0
0

Analyst Forecast on Prothena Plc Stock (PRTA)

What analysts predicted

Upside of 249.74%

Target:

$52.29

Current:

$14.95

Insights on Prothena Plc Stock (Ticker Symbol: PRTA)

  • Price Movement

    In the last 1 month, PRTA stock has moved up by 3.5%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 970.0K → 2.12M (in $), with an average increase of 54.3% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -59.00M → -57.95M (in $), with an average increase of 1.8% per quarter
  • PRTA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 115.5%
  • PRTA vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 102.7%
  • Price to Sales

    ForPRTA every $1 of sales, investors are willing to pay $5.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

PRTA Prothena Plc Financials in INR & Dollars

FY19Y/Y Change
Revenue
$814.0K
↓ 14.76%
Net Income
$-77.7M
↓ 50.09%
Net Profit Margin
-9.5K%
↑ 6755.28%
FY20Y/Y Change
Revenue
$853.0K
↑ 4.79%
Net Income
$-111.1M
↑ 43.08%
Net Profit Margin
-13.0K%
↓ 3487.15%
FY21Y/Y Change
Revenue
$200.6M
↑ 23414.3%
Net Income
$67.0M
↓ 160.26%
Net Profit Margin
33.39%
↑ 13063.17%
FY22Y/Y Change
Revenue
$53.9M
↓ 73.13%
Net Income
$-116.9M
↓ 274.62%
Net Profit Margin
-216.95%
↓ 250.34%
FY23Y/Y Change
Revenue
$91.4M
↑ 69.5%
Net Income
$-147.0M
↑ 25.72%
Net Profit Margin
-160.91%
↑ 56.04%
FY24Y/Y Change
Revenue
$135.2M
↑ 47.92%
Net Income
$-122.3M
↓ 16.81%
Net Profit Margin
-90.49%
↑ 70.42%
Q3 FY23Q/Q Change
Revenue
$84.9M
↑ 2011.62%
Net Income
$21.9M
↓ 140.13%
Net Profit Margin
25.81%
↑ 1384.23%
Q4 FY23Q/Q Change
Revenue
$316.0K
↓ 99.63%
Net Income
$-67.5M
↓ 408.01%
Net Profit Margin
-21.4K%
↓ 21378.97%
Q1 FY24Q/Q Change
Revenue
$50.0K
↓ 84.18%
Net Income
$-72.2M
↑ 7.06%
Net Profit Margin
-144.5K%
↓ 123124.84%
Q2 FY24Q/Q Change
Revenue
$132.0M
↑ 263928.0%
Net Income
$66.9M
↓ 192.59%
Net Profit Margin
50.67%
↑ 144528.67%
Q3 FY24Q/Q Change
Revenue
$970.0K
↓ 99.27%
Net Income
$-59.0M
↓ 188.21%
Net Profit Margin
-6.1K%
↓ 6133.25%
Q4 FY24Q/Q Change
Revenue
$2.1M
↑ 118.87%
Net Income
$-58.0M
↓ 1.77%
Net Profit Margin
-2.7K%
↑ 3352.67%
FY19Y/Y Change
Profit
$-50.0M
↓ 5337.91%
FY20Y/Y Change
Profit
$853.0K
↓ 101.71%
FY21Y/Y Change
Profit
$200.6M
↑ 23414.3%
FY22Y/Y Change
Profit
$53.9M
↓ 73.13%
FY23Y/Y Change
Profit
$-129.2M
↓ 339.68%
FY24Y/Y Change
Profit
$135.2M
↓ 204.61%
Q3 FY23Q/Q Change
Profit
$82.6M
↑ 3621.96%
Q4 FY23Q/Q Change
Profit
$-14.0M
↓ 116.92%
Q1 FY24Q/Q Change
Profit
$-837.0K
↓ 94.01%
Q2 FY24Q/Q Change
Profit
$74.5M
↓ 9001.31%
Q3 FY24Q/Q Change
Profit
$970.0K
↓ 98.7%
Q4 FY24Q/Q Change
Profit
$2.1M
↑ 118.87%
FY19Y/Y Change
Operating Cash Flow
$-53.0M
↑ 87.33%
Investing Cash Flow
$-547.0K
↓ 68.36%
Financing Cash Flow
$228.0K
↓ 99.43%
FY20Y/Y Change
Operating Cash Flow
$-80.4M
↑ 51.72%
Investing Cash Flow
$-196.0K
↓ 64.17%
Financing Cash Flow
$215.0K
↓ 5.7%
FY21Y/Y Change
Operating Cash Flow
$92.6M
↓ 215.23%
Investing Cash Flow
$-575.0K
↑ 193.37%
Financing Cash Flow
$190.3M
↑ 88426.51%
FY22Y/Y Change
Operating Cash Flow
$-108.8M
↓ 217.51%
Investing Cash Flow
$-464.0K
↓ 19.3%
Financing Cash Flow
$241.5M
↑ 26.86%
Q3 FY23Q/Q Change
Operating Cash Flow
$9.5M
↓ 121.18%
Investing Cash Flow
$-442.0K
↓ 42.67%
Financing Cash Flow
$2.7M
↓ 85.44%

Prothena Plc Technicals Summary

Sell

Neutral

Buy

Prothena Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Prothena Plc (PRTA) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prothena Corporation Plc logo
3.17%
-27.92%
-49.05%
-50.61%
60.93%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prothena Corporation Plc logo
35.44
NA
0.8
-3.58
-0.23
-0.16
NA
9.05
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prothena Corporation Plc logo
Buy
$804.7M
60.93%
35.44
-90.5%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Prothena Plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Organization
Prothena Plc
Employees
163
CEO
Dr. Gene G. Kinney Ph.D.
Industry
Health Technology

Management People of Prothena Plc

NameTitle
Dr. Gene G. Kinney Ph.D.
President, CEO & Director
Mr. Tran B. Nguyen M.B.A.
CFO & Chief Strategy Officer
Mr. Brandon S. Smith
Chief Operating Officer
Ms. Carol D. Karp
Chief Regulatory Officer
Dr. Wagner M. Zago Ph.D.
Chief Scientific Officer
Mr. Mark C. Johnson C.F.A.
Vice President of Investor Relations
Mr. Michael J. Malecek
Chief Legal Officer & Company Secretary
Mr. David A. Ford
Chief People Officer
Dr. Chad J. Swanson Ph.D.
Chief Development Officer

Important FAQs about investing in PRTA Stock from India :

What is Prothena Plc share price today?

Prothena Plc share price today stands at $14.95, Open: $15.03 ; Previous Close: $15.06 ; High: $15.46 ; Low: $14.33 ; 52 Week High: $30.85 ; 52 Week Low: $11.70.

The stock opens at $15.03, after a previous close of $15.06. The stock reached a daily high of $15.46 and a low of $14.33, with a 52-week high of $30.85 and a 52-week low of $11.70.

Can Indians buy Prothena Plc shares?

Yes, Indians can invest in the Prothena Plc (PRTA) from India.

With INDmoney, you can buy Prothena Plc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Prothena Plc at zero transaction cost.

How can I buy Prothena Plc shares from India?

It is very easy to buy Prothena Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Prothena Plc (PRTA) be purchased?

Yes, you can buy fractional shares of Prothena Plc with INDmoney app.

What are the documents required to start investing in Prothena Plc stocks?

To start investing in Prothena Plc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Prothena Plc Stock (PRTA)?

Today’s highest price of Prothena Plc (PRTA) is $15.46.

Today’s lowest price of Prothena Plc (PRTA) is $14.33.

What is today's market capitalisation of Prothena Plc?

Today's market capitalisation of Prothena Plc PRTA is 804.7M

What is the 52 Week High and Low Range of Prothena Plc Stock (PRTA)?

  • 52 Week High

    $30.85

  • 52 Week Low

    $11.70

What are the historical returns of Prothena Plc (PRTA)?

  • 1 Month Returns

    3.17%

  • 3 Months Returns

    -27.92%

  • 1 Year Returns

    -49.05%

  • 5 Years Returns

    60.93%

Who is the Chief Executive Officer (CEO) of Prothena Plc ?

Dr. Gene G. Kinney Ph.D. is the current Chief Executive Officer (CEO) of Prothena Plc.